Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT (Unaudited)

v3.21.2
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT (Unaudited) - USD ($)
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Total
Beginning balance, shares at Dec. 31, 2019 310,111,536      
Beginning balance, value at Dec. 31, 2019 $ 310,111 $ 116,209,889 $ (118,789,000) $ (2,269,000)
Common stock issued on exercise of warrants and options, shares 1,215,000      
Common stock issued on exercise of warrants and options, value $ 1,215 59,785 61,000
Common stock issued on conversion of notes payable, shares 3,645,673      
Common stock issued on conversion of notes payable, value $ 3,646 215,354 219,000
Fair value of warrants and beneficial conversion feature of issued convertible notes 35,000 35,000
Fair value of options and warrants issued as compensation 121,000 121,000
Net loss (766,000) (766,000)
Ending balance, shares at Mar. 31, 2020 314,972,209      
Ending balance, value at Mar. 31, 2020 $ 314,972 116,641,028 (119,555,000) (2,599,000)
Beginning balance, shares at Dec. 31, 2020 323,181,243      
Beginning balance, value at Dec. 31, 2020 $ 323,182 117,373,818 (121,204,000) (3,507,000)
Adjustment for adoption of ASU 2020-06   (60,000) 30,000 (30,000)
Common stock issued on conversion of notes payable, shares 2,200,000      
Common stock issued on conversion of notes payable, value $ 2,200 41,800 44,000
Fair value of warrants and beneficial conversion feature of issued convertible notes 30,000 30,000
Fair value of options and warrants issued as compensation 13,000 13,000
Fair value of common stock issued in private sale of securities, shares 3,000,000      
Fair value of common stock issued in private sale of securities, value $ 3,000 42,000 45,000
Net loss (371,000) (371,000)
Ending balance, shares at Mar. 31, 2021 328,381,243      
Ending balance, value at Mar. 31, 2021 $ 328,382 $ 117,400,618 $ (121,545,000) $ (3,776,000)